Halozyme Therapeutics, Inc. (OQ:HALO)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 12390 EL CAMINO REAL
SAN DIEGO CA 92130
Tel: 1-609-3593016
Website: https://www.halozyme.com
IR: See website
<
Key People
Helen I. Torley
President, Chief Executive Officer, Director
Nicole Labrosse
Chief Financial Officer, Senior Vice President
Michael J. Labarre
Senior Vice President, Chief Technical Officer
Mark Snyder
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
   
Business Overview
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
Financial Overview
For the fiscal year ended 31 December 2023, Halozyme Therapeutics, Inc. revenues increased 26% to $829.3M. Net income increased 39% to $281.6M. Revenues reflect Royalties segment increase of 24% to $447.9M, Hylenex segment increase of 80% to $130.8M, United States segment increase of 34% to $587.2M, Belgium segment increase from $2.1M to $58.4M. Net income benefited from Investment and other income increase from $1M to $16.3M (income).
Employees: 373 as of Feb 12, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $6,256M as of Dec 31, 2023
Annual revenue (TTM): $829.25M as of Dec 31, 2023
EBITDA (TTM): $422.43M as of Dec 31, 2023
Net annual income (TTM): $281.59M as of Dec 31, 2023
Free cash flow (TTM): $373.28M as of Dec 31, 2023
Net Debt Last Fiscal Year: $1,163M as of Dec 31, 2023
Shares outstanding: 127,054,240 as of Feb 26, 2024
Index Membership: S&P 400 Mid Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.